134 related articles for article (PubMed ID: 10786675)
1. Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors.
Darnell JC; Albert ML; Darnell RB
Cancer Res; 2000 Apr; 60(8):2136-9. PubMed ID: 10786675
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific killer cells in paraneoplastic cerebellar degeneration.
Albert ML; Darnell JC; Bender A; Francisco LM; Bhardwaj N; Darnell RB
Nat Med; 1998 Nov; 4(11):1321-4. PubMed ID: 9809559
[TBL] [Abstract][Full Text] [Related]
3. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration.
Albert ML; Austin LM; Darnell RB
Ann Neurol; 2000 Jan; 47(1):9-17. PubMed ID: 10632096
[TBL] [Abstract][Full Text] [Related]
4. An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies.
Sutton IJ; Steele J; Savage CO; Winer JB; Young LS
J Neuroimmunol; 2004 May; 150(1-2):98-106. PubMed ID: 15081253
[TBL] [Abstract][Full Text] [Related]
5. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration.
Furneaux HM; Rosenblum MK; Dalmau J; Wong E; Woodruff P; Graus F; Posner JB
N Engl J Med; 1990 Jun; 322(26):1844-51. PubMed ID: 2348838
[TBL] [Abstract][Full Text] [Related]
6. [Importance of plasmapheresis in the treatment of paraneoplastic cerebellar degeneration].
Basić-Jukić N; Kes P; Basić-Kes V; Brunetta B
Acta Med Croatica; 2004; 58(1):63-6. PubMed ID: 15125396
[TBL] [Abstract][Full Text] [Related]
7. Proteasome antibodies in paraneoplastic cerebellar degeneration.
Storstein A; Knudsen A; Vedeler CA
J Neuroimmunol; 2005 Aug; 165(1-2):172-8. PubMed ID: 15964637
[TBL] [Abstract][Full Text] [Related]
8. Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Balamurugan K; Luu VD; Kaufmann MR; Hofmann VS; Boysen G; Barth S; Bordoli MR; Stiehl DP; Moch H; Schraml P; Wenger RH; Camenisch G
Oncogene; 2009 Sep; 28(37):3274-85. PubMed ID: 19581925
[TBL] [Abstract][Full Text] [Related]
9. CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
Eichler TW; Totland C; Haugen M; Qvale TH; Mazengia K; Storstein A; Haukanes BI; Vedeler CA
PLoS One; 2013; 8(6):e66002. PubMed ID: 23823982
[TBL] [Abstract][Full Text] [Related]
10. [Paraneoplastic cerebellar degeneration associated with ovarian cancer: anti-Yo immunoreactivity in autoptic cerebellum and ovarian carcinoma].
Bartos A; Stourac P; Rusina R; Sejdová M; Velenská Z
Nervenarzt; 2002 Oct; 73(10):995-8. PubMed ID: 12376889
[TBL] [Abstract][Full Text] [Related]
11. Induction of cytotoxic T lymphocytes specific for paraneoplastic cerebellar degeneration-associated antigen in vivo by DNA immunization.
Sakai K; Shirakawa T; Kitagawa Y; Li Y; Hirose G
J Autoimmun; 2001 Dec; 17(4):297-302. PubMed ID: 11771954
[TBL] [Abstract][Full Text] [Related]
12. Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.
Raspotnig M; Haugen M; Thorsteinsdottir M; Stefansson I; Salvesen HB; Storstein A; Vedeler CA
Cancer Immunol Immunother; 2017 Nov; 66(11):1463-1471. PubMed ID: 28710511
[TBL] [Abstract][Full Text] [Related]
13. The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival.
Okano HJ; Park WY; Corradi JP; Darnell RB
Genes Dev; 1999 Aug; 13(16):2087-97. PubMed ID: 10465786
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
[TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.
Rojas-Marcos I; Picard G; Chinchón D; Gelpi E; Psimaras D; Giometto B; Delattre JY; Honnorat J; Graus F
Neuro Oncol; 2012 Apr; 14(4):506-10. PubMed ID: 22351748
[TBL] [Abstract][Full Text] [Related]
16. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique.
Monstad SE; Storstein A; Dørum A; Knudsen A; Lønning PE; Salvesen HB; Aarseth JH; Vedeler CA
Clin Exp Immunol; 2006 Apr; 144(1):53-8. PubMed ID: 16542365
[TBL] [Abstract][Full Text] [Related]
17. Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study.
Brieva-Ruíz L; Diaz-Hurtado M; Matias-Guiu X; Márquez-Medina D; Tarragona J; Graus F
Clin Neurol Neurosurg; 2008 Dec; 110(10):1044-6. PubMed ID: 18701208
[TBL] [Abstract][Full Text] [Related]
18. A T-cell receptor associated with naturally occurring human tumor immunity.
Santomasso BD; Roberts WK; Thomas A; Williams T; Blachère NE; Dudley ME; Houghton AN; Posner JB; Darnell RB
Proc Natl Acad Sci U S A; 2007 Nov; 104(48):19073-8. PubMed ID: 18045792
[TBL] [Abstract][Full Text] [Related]
19. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies.
Storstein A; Krossnes BK; Vedeler CA
Acta Neurol Scand; 2009 Jul; 120(1):64-7. PubMed ID: 19486326
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration.
Carpenter EL; Vance BA; Klein RS; Voloschin A; Dalmau J; Vonderheide RH
J Neuroimmunol; 2008 Jan; 193(1-2):173-82. PubMed ID: 18053582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
